Stage 4 nsclc prognosis
Searched over 200M research papers
Summary
2 papers analyzed
These studies suggest that stage IV non-small-cell lung cancer patients with EGFR-sensitizing mutations have a significantly better prognosis.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Prognosis of Stage 4 Non-Small Cell Lung Cancer (NSCLC)
Impact of Sex on Prognosis in Stage 4 NSCLC
Survival Rates by Sex
Research indicates that sex is a significant prognostic factor in stage 4 non-small cell lung cancer (NSCLC). Females generally have a better prognosis compared to males. A study analyzing clinical data from multiple sources found that the median overall survival (OS) time for females was 19 months, compared to 12 months for males. This difference is statistically significant, with females showing a lower risk of death (HR = 0.77; 95% CI: 0.68-0.87; P < 0.001).
EGFR Mutation and Treatment Response
The presence of EGFR-sensitizing mutations further enhances the survival advantage for females. Females with these mutations had a median OS of 32 months, compared to 19 months for males with the same mutations. Additionally, females benefited more from EGFR inhibitors in terms of both progression-free survival (PFS) and OS, with a median PFS of 21 months for females versus 12 months for males (P < 0.001).
Treatment Approaches and Long-Term Survival
Chemo-Radiotherapy Outcomes
While the primary focus is on stage 4 NSCLC, insights from stage III sub-groups treated with chemo-radiotherapy can provide valuable context. A study on patients with stage T4N0-1 and single station IIIA-N2 NSCLC treated with individualized isotoxic accelerated radiotherapy (INDAR) and chemotherapy showed promising results. The median OS for T4N0-1 patients was 34 months, with a 2-year survival rate of 55% and a 5-year survival rate of 25%. For stage IIIA-N2 patients, the median OS was 26 months, with 2- and 5-year survival rates of 53% and 24%, respectively.
Conclusion
In summary, sex is a crucial factor in the prognosis of stage 4 NSCLC, with females generally having better survival outcomes than males. The presence of EGFR-sensitizing mutations further improves prognosis, particularly for females. Additionally, while not directly related to stage 4, the use of individualized isotoxic accelerated radiotherapy (INDAR) in stage III sub-groups shows promising long-term survival outcomes, which may inform treatment strategies for advanced stages. Understanding these factors can help in tailoring more effective treatment plans and improving survival rates for stage 4 NSCLC patients.
Sources and full results
Most relevant research papers on this topic
